DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)

Market Cap	244.18B -5.8%
Revenue (ttm)	143.06B -4.3%
Net Income	1.65B +211.2%
EPS	94.00 +213.3%
Shares Out	17.52M
PE Ratio	148.30
Forward PE	n/a
Dividend	150.00 (1.06%)
Ex-Dividend Date	Dec 29, 2025

Volume	49,967
Average Volume	61,200
Open	14,170
Previous Close	14,150
Day's Range	13,850 - 14,170
52-Week Range	12,610 - 24,900
Beta	-0.11
RSI	44.63
Earnings Date	May 14, 2026

About DAE HWA Pharmaceutical

DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, u...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 308
• Stock Exchange: KOSDAQ
• Ticker Symbol: 067080

Financial Performance

In 2025, DAE HWA Pharmaceutical's revenue was 143.06 billion, a decrease of -4.25% compared to the previous year's 149.41 billion. Earnings were 1.65 billion, an increase of 211.15%.